Tag: KDC-MN-142

  • Atomoxetine

    Selective norepinephrine reuptake inhibitor

    A selective NRI FDA-approved as Strattera for ADHD, the first non-stimulant FDA-approved for the indication.

    Abstract

    Atomoxetine (Strattera; CAS 83015-26-3; molecular formula C17H21NO; molecular weight 255.36) is a selective norepinephrine reuptake inhibitor (NRI) developed by Eli Lilly and approved by the FDA in 2002 for ADHD in children, adolescents, and adults. The compound is the first non-stimulant FDA-approved for ADHD. Mechanism is NET inhibition; the compound is essentially inactive at DAT and SERT. Pharmacokinetics: plasma half-life 5.2 hours in extensive metabolizers via CYP2D6, 21.6 hours in poor metabolizers; doses are titrated based on response and tolerability. Schedule status: not scheduled (distinguishing it from amphetamine and methylphenidate ADHD therapies).

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.